Casi Pharmaceuticals earnings were -$40.5M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest CASI earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$10.8M, down 25.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CASI reported annual earnings of -$39.3M, with 45.6% growth.
Casi Pharmaceuticals Earnings Reports & History FAQ
What were Casi Pharmaceuticals's earnings last quarter?
On CASI's earnings call on Invalid Date, Casi Pharmaceuticals (NASDAQ: CASI) reported Q1 2025 earnings per share (EPS) of -$0.69, up 2.82% year over year. Total CASI earnings for the quarter were -$10.75 million. In the same quarter last year, Casi Pharmaceuticals's earnings per share (EPS) was -$0.71.
Is Casi Pharmaceuticals profitable or losing money?
As of the last Casi Pharmaceuticals earnings report, Casi Pharmaceuticals is currently losing money. Casi Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$40.48 million, a 32.91% increase year over year.
What was CASI's earnings growth in the past year?
As of Casi Pharmaceuticals's earnings date in Invalid Date, Casi Pharmaceuticals's earnings has grown year over year. CASI earnings in the past year totalled -$40.48 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.